CAMBRIDGE, Mass.--(BUSINESS WIRE)--Anida Pharma, Inc. announced today that it has been awarded funding by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to conduct pre-clinical research using its lead compound for treatment of neurodegenerative diseases, Neuroprotectin D1 (NPD1). This is Anida Pharma’s first grant from MJFF. “The grant will not only provide funding but, equally important, will bring Anida into the network of outstanding experts that support MJFF’s mission to accelerate translational research and bring new disease-modifying treatment options to patients with Parkinson’s disease. The collaboration marks a significant step for Anida, and we will be looking forward to building our scientific relationship with the Foundation,” said Per Gjorstrup, MD, PhD, President and CEO of Anida Pharma.
Help employers find you! Check out all the jobs and post your resume.
